TipRanks
PharmAla Biotech Holdings, Inc. (TSE:MDMA)
:MDMA
Canadian Market
MDMA
PharmAla Biotech Holdings, Inc.
RESEARCH TOOLSreports
Want to see TSE:MDMA full AI Analyst Report?

PharmAla Biotech Holdings, Inc. (MDMA) Ratios

66 Followers

PharmAla Biotech Holdings, Inc. Ratios

TSE:MDMA's free cash flow for Q3 2026 was C$0.66. For the 2026 fiscal year, TSE:MDMA's free cash flow was decreased by C$ and operating cash flow was C$-0.92. See a summary of the company’s cash flow.
Ratios
TTM
Nov 25Nov 24Nov 23Nov 22
Liquidity Ratios
Current Ratio
 1.17 1.71 1.14 0.69 2.56
Quick Ratio
 0.64 1.33 0.75 0.58 2.29
Cash Ratio
 0.08 0.04 0.46 0.19 2.01
Solvency Ratio
 -1.28 -2.14 -0.82 -0.71 -2.30
Operating Cash Flow Ratio
 -0.85 -1.09 -0.35 -0.33 -1.48
Short-Term Operating Cash Flow Coverage
 0.00 0.00 0.00 -1.34 0.00
Net Current Asset Value
C$ 193.02KC$ 685.13KC$ 126.56KC$ -315.07KC$ 661.69K
Leverage Ratios
Debt-to-Assets Ratio
 0.00 0.00 0.00 0.11 0.00
Debt-to-Equity Ratio
 0.00 0.00 0.00 0.18 0.00
Debt-to-Capital Ratio
 0.00 0.00 0.00 0.15 0.00
Long-Term Debt-to-Capital Ratio
 0.00 0.00 0.00 0.00 0.00
Financial Leverage Ratio
 1.59 1.39 1.46 1.74 1.22
Debt Service Coverage Ratio
 0.00 0.00 0.00 -2.80 0.00
Interest Coverage Ratio
 0.00 0.00 0.00 0.00 0.00
Debt to Market Cap
 0.00 0.00 0.00 0.01 0.00
Interest Debt Per Share
 0.00 0.00 0.00 <0.01 0.00
Net Debt to EBITDA
 0.06 0.02 0.73 -0.08 0.88
Profitability Margins
Gross Profit Margin
-24.49%-139.58%85.72%85.36%97.07%
EBIT Margin
-127.79%-361.50%-62.16%-143.41%-1262.43%
EBITDA Margin
-115.90%-342.17%-55.38%-133.49%-1246.89%
Operating Profit Margin
-120.21%-355.61%-62.16%-143.41%-1262.43%
Pretax Profit Margin
-126.87%-359.25%-79.55%-146.58%-1262.43%
Net Profit Margin
-126.87%-359.25%-79.55%-146.58%-1262.43%
Continuous Operations Profit Margin
-126.87%-359.25%-79.55%-146.58%-1262.43%
Net Income Per EBT
100.00%100.00%100.00%100.00%100.00%
EBT Per EBIT
105.54%101.02%127.97%102.21%100.00%
Return on Assets (ROA)
-52.39%-63.61%-28.42%-32.32%-42.30%
Return on Equity (ROE)
-72.15%-88.49%-41.57%-56.36%-51.70%
Return on Capital Employed (ROCE)
-78.96%-87.60%-32.48%-55.15%-51.70%
Return on Invested Capital (ROIC)
-78.96%-87.60%-26.27%-46.61%-51.70%
Return on Tangible Assets
-120.43%-131.85%-78.90%-108.90%-90.48%
Earnings Yield
-6.02%-16.18%-10.94%-4.19%-23.75%
Efficiency Ratios
Receivables Turnover
 2.63 2.29 4.90 2.38 1.54
Payables Turnover
 2.27 3.12 0.41 0.16 <0.01
Inventory Turnover
 2.63 3.92 0.42 0.64 0.02
Fixed Asset Turnover
 584.97 207.50 2.58K 253.09 20.55
Asset Turnover
 0.41 0.18 0.36 0.22 0.03
Working Capital Turnover Ratio
 4.19 1.49 -10.98 3.07 0.05
Cash Conversion Cycle
 117.26 135.36 63.04 -1.54K -40.49K
Days of Sales Outstanding
 138.88 159.18 74.52 153.33 236.34
Days of Inventory Outstanding
 139.01 93.02 872.74 572.50 18.56K
Days of Payables Outstanding
 160.63 116.84 884.22 2.27K 59.29K
Operating Cycle
 277.89 252.20 947.26 725.83 18.80K
Cash Flow Ratios
Operating Cash Flow Per Share
 >-0.01 -0.01 >-0.01 >-0.01 >-0.01
Free Cash Flow Per Share
 >-0.01 -0.01 >-0.01 -0.01 -0.02
CapEx Per Share
 <0.01 <0.01 <0.01 <0.01 0.01
Free Cash Flow to Operating Cash Flow
 1.03 1.00 1.70 2.49 2.59
Dividend Paid and CapEx Coverage Ratio
 -26.80 -358.41 -1.42 -0.67 -0.63
Capital Expenditure Coverage Ratio
 -26.80 -358.41 -1.42 -0.67 -0.63
Operating Cash Flow Coverage Ratio
 0.00 0.00 0.00 -1.34 0.00
Operating Cash Flow to Sales Ratio
 -0.76 -1.72 -0.31 -0.64 -8.01
Free Cash Flow Yield
-3.71%-7.79%-7.28%-4.55%-39.04%
Valuation Ratios
Price-to-Earnings (P/E) Ratio
 -16.44 -6.19 -9.14 -23.85 -4.21
Price-to-Sales (P/S) Ratio
 21.11 22.20 7.27 34.95 53.16
Price-to-Book (P/B) Ratio
 13.84 5.47 3.80 13.44 2.18
Price-to-Free Cash Flow (P/FCF) Ratio
 -26.93 -12.84 -13.74 -21.97 -2.56
Price-to-Operating Cash Flow Ratio
 -27.58 -12.88 -23.43 -54.75 -6.64
Price-to-Earnings Growth (PEG) Ratio
 -0.54 -0.05 -8.41 1.05 0.07
Price-to-Fair Value
 13.84 5.47 3.80 13.44 2.18
Enterprise Value Multiple
 -18.15 -6.47 -12.40 -26.27 -3.39
Enterprise Value
 26.66M 13.40M 7.11M 18.65M 3.30M
EV to EBITDA
 -18.15 -6.47 -12.40 -26.27 -3.39
EV to Sales
 21.03 22.13 6.87 35.06 42.24
EV to Free Cash Flow
 -26.83 -12.81 -12.98 -22.04 -2.04
EV to Operating Cash Flow
 -27.53 -12.84 -22.12 -54.92 -5.27
Tangible Book Value Per Share
 <0.01 <0.01 <0.01 >-0.01 0.02
Shareholders’ Equity Per Share
 0.02 0.02 0.02 0.02 0.02
Tax and Other Ratios
Effective Tax Rate
 0.00 0.00 0.19 0.00 <0.01
Revenue Per Share
 0.01 <0.01 0.01 <0.01 <0.01
Net Income Per Share
 -0.01 -0.02 >-0.01 >-0.01 -0.01
Tax Burden
 1.00 1.00 1.00 1.00 1.00
Interest Burden
 0.99 0.99 1.28 1.02 1.00
Research & Development to Revenue
 0.14 0.40 0.12 -0.31 0.00
SG&A to Revenue
 1.44 1.76 1.16 2.17 13.44
Stock-Based Compensation to Revenue
 0.44 1.53 0.52 0.13 3.03
Income Quality
 0.60 0.48 0.39 0.44 0.63
Currency in CAD